Loading
NASDAQHealthcareBiotechnology
Latest quote
$2.33
−$0.16 · -6.43%
Ernexa Therapeutics Inc. is a biotechnology firm currently in its preclinical development phase, specializing in the creation of therapeutic interventions using induced mesenchymal stem cells (iMSCs). The company's primary focus lies in addressing solid tumor cancers and a range of autoimmune diseases. Its flagship candidate, ERNA-101, is an allogeneic iMSC designed to release pro-inflammatory cytokines, namely IL-7 and IL-15, intended for the treatment of ovarian cancer. Additionally, Ernexa is developing ERNA-102, an iMSC product engineered to secrete the anti-inflammatory cytokine IL-10, aimed at managing rheumatoid arthritis. The company has a licensing arrangement in place with Factor Bioscience Limited. Established in 2018, this Cambridge, Massachusetts-based entity operated as Eterna Therapeutics Inc. until its rebranding to Ernexa Therapeutics in March 2025.
Regular session
$2.33
−$0.16 · -6.43%
Regular session · ET · Market data may be delayed.
Ernexa Therapeutics Inc. is a biotechnology firm currently in its preclinical development phase, specializing in the creation of therapeutic interventions using induced mesenchymal stem cells (iMSCs). The company's primary focus lies in addressing solid tumor cancers and a range of autoimmune diseases. Its flagship candidate, ERNA-101, is an allogeneic iMSC designed to release pro-inflammatory cytokines, namely IL-7 and IL-15, intended for the treatment of ovarian cancer. Additionally, Ernexa is developing ERNA-102, an iMSC product engineered to secrete the anti-inflammatory cytokine IL-10, aimed at managing rheumatoid arthritis. The company has a licensing arrangement in place with Factor Bioscience Limited. Established in 2018, this Cambridge, Massachusetts-based entity operated as Eterna Therapeutics Inc. until its rebranding to Ernexa Therapeutics in March 2025.
Day range
Current $2.33
52-week range
Current $2.33
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
22
Expensive
Sentiment
59
Mixed
Risk
79
High Risk
Momentum
17
Strong Down
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Ernexa Therapeutics Inc. is a biotechnology firm currently in its preclinical development phase, specializing in the creation of therapeutic interventions using induced mesenchymal stem cells (iMSCs). The company's primary focus lies in addressing solid tumor cancers and a range of autoimmune diseases. Its flagship candidate, ERNA-101, is an allogeneic iMSC designed to release pro-inflammatory cytokines, namely IL-7 and IL-15, intended for the treatment of ovarian cancer. Additionally, Ernexa is developing ERNA-102, an iMSC product engineered to secrete the anti-inflammatory cytokine IL-10, aimed at managing rheumatoid arthritis. The company has a licensing arrangement in place with Factor Bioscience Limited. Established in 2018, this Cambridge, Massachusetts-based entity operated as Eterna Therapeutics Inc. until its rebranding to Ernexa Therapeutics in March 2025.
Day range
Current $2.33
52-week range
Current $2.33
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | — | 582K USD | 68K USD | — | — |
| Cost of goods sold | — | 96K USD | 236K USD | — | — |
| Gross profit | — | 486K USD | −168K USD | — | — |
| Research and development | 4.16M USD | 4.6M USD | 5.92M USD | 10.39M USD | 12.71M USD |
| Selling, general, and administrative | 5.16M USD | 13.13M USD | 14.59M USD | 16.56M USD | 14.72M USD |
| Operating expenses | 9.32M USD | 16.16M USD | 20.97M USD | 33.22M USD | 113.73M USD |
| Interest income | 83K USD | 249K USD | 138K USD | — | — |
| Interest expense | 27K USD | 6.75M USD | 614K USD | 30K USD | 74K USD |
| Depreciation and amortization | 263K USD | 1.64M USD | 1.12M USD | 497K USD | 459K USD |
| Operating income | −9.32M USD | −15.67M USD | −21.14M USD | −33.22M USD | −113.73M USD |
| Net income | −14.08M USD | −44.54M USD | −21.67M USD | −24.58M USD | −122.55M USD |
Company facts updated Oct 9, 2026.
Reported history and fiscal-year consensus
Reported history and fiscal-year consensus
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
